Cencora, Inc.
CORCencora, Inc. (COR), formerly known as McKesson Corporation, is a global health care company that distributes pharmaceuticals, healthcare products, and medical supplies. It provides supply chain management, technology solutions, and healthcare services to hospitals, pharmacies, and other healthcare providers. The company plays a key role in ensuring the efficient flow of essential medical products across the healthcare industry.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 1, 2026 | $0.60 | 2026-05-15 | 2026-05-15 |
| March 2, 2026 | $0.60 | 2026-02-13 | 2026-02-13 |
| December 1, 2025 | $0.60 | 2025-11-14 | 2025-11-14 |
| September 3, 2025 | $0.55 | 2025-08-15 | 2025-08-15 |
| June 2, 2025 | $0.55 | 2025-05-16 | 2025-05-16 |
Dividends Summary
- Consistent Payer: Cencora, Inc. has rewarded shareholders with 90 dividend payments over the past 22 years.
- Total Returned Value: Investors who held COR shares during this period received a total of $24.55 per share in dividend income.
- Latest Payout: The most recent dividend of $0.60/share was paid 47 days ago, on June 1, 2026.
- Yield & Schedule: COR currently pays dividends quarterly with an annual yield of 0.76%.
- Dividend Growth: Since 2004, the dividend payout has grown by 2300.0%, from $0.03 to $0.60.
- Dividend Reliability: COR has maintained or increased its dividend for 68 consecutive payments.
Company News
The Schall Law Firm is investigating Cencora, Inc. for potential securities law violations following the company's Q2 2026 earnings miss and guidance reduction on May 6, 2026. Cencora attributed a $2 billion revenue headwind to manufactured list price reductions, causing its stock to plummet 17.4% on the announcement. The investigation focuses on...
Cencora reported Q1 fiscal year revenue of $85.93 billion, slightly missing Wall Street estimates of $86.03 billion, but beat earnings expectations with adjusted EPS of $4.08 versus consensus of $4.03. The company raised its 2026 sales growth guidance from 5%-7% to 7%-9% and increased full-year sales guidance to $343.79-$350.22 billion. However, ...
The global comparator drug sourcing market is projected to grow from USD 1.42 billion in 2025 to USD 2.72 billion by 2033, at a CAGR of 8.47%. Growth is driven by increasing global clinical trials, rising complexity of biologics, and growing outsourcing trends. North America leads with 44.60% market share, while Asia-Pacific is the fastest-growin...
AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing...
Cencora agreed to acquire a majority stake in OneOncology for $5 billion, funded through new debt financing. The transaction is expected to close by the end of fiscal 2026 second quarter and is anticipated to be earnings neutral in the first twelve months.
